Colorectal cancer: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• TP53 6
• KRAS 56
• PD-1 108
• BRAF 36
• EGFR 32
• PD-L1 26
• PI3K 2
• STAT3 0
• CTNNB1 1
• AKT 0
• RAS 31
• HER2 38
• mTOR 1
• MAPK 1
• VEGF 14
• ERK 0
• STING 0
• NRF2 0
• PPAR 0
• CTLA-4 16
• HIF-1 0
• COX-2 5
• JNK 0
• AMPK 0
• MYC 0
• PTEN 1
• YAP 0
• GPX4 0
• NRAS 8
• IL-6 0
• JAK 0
• MET 7
• PARP 1
• CXCR4 0
• TNF 0
• NLRP3 0
• BCL-2 0
• HSP90 0
• PIK3CA 2
• GLP-1 1
• HDAC 2
• METTL3 0
• CDK4/6 2
• MEK 1
• CD47 1
• FGFR 0
• BRCA1 1
• NTRK 1
• B7-H3 5
• EZH2 0
• FAK 1
• HMGB1 0
• TROP2 4
• MUC1 2
• ATM 2
• IDO1 1
• IL-1 0
• PCSK9 3
• PINK1 0
• SHP2 0

6 of 6+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NCI · R43

  Novel macrophage repolarization therapy for colorectal cancer

  Panorama Research, Inc.· Sunnyvale, United States· US$387,240 awarded in fiscal year 2026· until Aug 2027

• NIH NIAID · R01

  Impact of bacterial phenotypic variation on phage resistance

  Institute for Systems Biology· Seattle, United States· US$874,085 awarded in fiscal year 2026· until Aug 2031

• NIH NINR · R01

  Community Health Centers Achieving Metrics and Primed for Success

  University of Pennsylvania· Philadelphia, United States· US$762,815 awarded in fiscal year 2026· until Jun 2031

• NIH NCI · K99

  Developing and Piloting a Multilevel Intervention to Address Nutritional Needs in the Outpatient Oncology Setting

  Yale University· New Haven, United States· US$168,290 awarded in fiscal year 2026· until Aug 2028

• NIH NCI · R01

  The role of IL-9 in gastric metaplasia and carcinogenesis

  Saint Louis University· Saint Louis, United States· US$2,541,122 awarded in fiscal year 2026· until Aug 2030

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Glycoanalytics-guided discovery of novel biomarkers and therapeutic glycoenzyme inhibitors for cancer (GLYCOANALYTICS)

  I3s - Instituto de Investigacao e Inovacao Em Saude Da Universidade Do Porto· Porto, Portugal· EU contribution €207,183· until Aug 2029

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Unravelling Glycosylation Codes in Cancer at the Molecular Level: An Interdisciplinary Approach for the Dissection of the Recognition Features of CD44 by Galectins and Selectins (GLYCODECD44)

  Asociacion Centro de Investigacion Cooperativa En Biociencias Cic Biogune· Derio Vizcaya, Spain· EU contribution €194,075· until Aug 2029

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  GUT-commensal Strain for Cancer Assessment and Notification (GUT-SCAN)

  Vib Vzw· Zwijnaarde - Gent, Belgium· EU contribution €200,400· until Mar 2029

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Ion channelome of solid tumours: Novel immunotherapy targets for cancer-specific mRNA and drug delivery (ION-CANDEL)

  Deutsches Krebsforschungszentrum Heidelberg· Heidelberg, Germany· EU contribution €217,965· until Jan 2029

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-DN-JD

  Target mining for the development of therapeutics against pathogen-induced cancers (TagTIC)

  Paris-Lodron-Universitat Salzburg· Salzburg, Austria· EU contribution €4,281,580· until Dec 2031· 9 countries

  The disease is named only in the funder's project summary, not in the title.

10 of 990 running projects, newest first. Listed amounts together: US$548.0m + €233.2m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  A Phase 1 Study of MRTX0902 in Solid Tumors With Mutations in the KRAS MAPK Pathway

  NCT05578092· Mirati Therapeutics Inc.· Updated 19 Feb 2026

  “business objectives have changed”Registry text, quoted unchanged. Source

• Terminated

  Study of IK-595 in RAS- or RAF-altered Advanced Tumors

  NCT06270082· Ikena Oncology· Updated 19 Sept 2025

  “Limited resources and strategic priorities”Registry text, quoted unchanged. Source

• Terminated

  Tovorafenib (DAY101) or in Combination With Pimasertib for Participants With Melanoma and Other Solid Tumors

  NCT07121829· Day One Biopharmaceuticals, Inc.· Updated 14 Aug 2025

  “Sponsor decision”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

No trial in this view states that it shares participant data.

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 134
• Organoids 108
• Mendelian Randomization Analysis 51
• CRISPR-Cas Systems 34
• Gene Expression Profiling 338
• Sequence Analysis, RNA 30
• Whole Genome Sequencing 22
• Exome Sequencing 26
• Proteomics 107
• Metabolomics 92
• Mass Spectrometry 42
• Flow Cytometry 113
• Immunohistochemistry 208
• Liquid Biopsy 36
• Circulating Tumor DNA 120
• Xenograft Model Antitumor Assays 432
• Positron-Emission Tomography 38
• Magnetic Resonance Imaging 196
• Machine Learning 211
• Deep Learning 142
• Cohort Studies 318
• Genome-Wide Association Study 66

• A Tissue Explant Model for Colon Cancer.

  Methods Mol Biol, Jan 2027

• Intestinal Organoids Culture in Synthetic Hydrogels.

  Methods Mol Biol, Jan 2027

• Comprehensive Isolation Strategy for Intestinal Epithelial and Fibroblast Cells from Healthy and Tumor Human Tissues.

  Methods Mol Biol, Jan 2027

• Impacts of mutation accumulation and order on tumor initiation revealed by engineered murine colorectal cancer organoids.

  Elife, Nov 2026

• The role of SARS1 in the progression of colorectal cancer: insights from clinical data and organoid models.

  PeerJ, Oct 2026

• Beyond the Monolayer: Leveraging 3D Culture Systems to Decode Mechanisms of Drug Resistance and Therapeutic Vulnerabilities in Colorectal Cancer.

  Cancer Med, Oct 2026

• Selective Macrocyclic WEE1 Kinase Inhibitors with Strong Efficacy against Patient-Derived Colorectal Cancer Organoids.

  J Med Chem, Sept 2026

• A Multimodal Framework to Assess Patient-Derived Colon Tumor Organoid-Immune Cell Co-cultures.

  J Vis Exp, Sept 2026

• Omega-3 polyunsaturated fatty acids and epigallocatechin-3-gallate attenuate obesity-associated CD44-high stemness in colorectal cancer through modulation of Notch1, Wnt/β-catenin and PI3K/mTOR signaling.

  Biomed Pharmacother, Sept 2026

• Patient-Derived Organoid and Single-Cell Multiomics Reveal Evolution Driven by CEACAM6/KRT19-Mediated Heterogeneity.

  FASEB J, Aug 2026

See which targets of this disease your abstract mentions, and go to the people working on them.